Rejected IND For HCV Asset May Put BioCryst/Presidio Merger At Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Two R&D setbacks in the past week have BioCryst repositioning itself for the near-term. In October, it announced a planned merger with privately held Presidio, which would create a new company with three hepatitis C candidates, all in different drug classes.